TRACON Pharmaceutical (TCON): Trial Approval In Both The US and Europe - Stifel

October 4, 2016 9:01 AM EDT
Get Alerts TCON Hot Sheet
Price: $5.30 -5.36%

Rating Summary:
    6 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade TCON Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Stifel analyst, Thomas Schrader, reiterated his Buy rating on shares of Tracon Pharmaceuticals (NASDAQ: TCON) after the company announced that the U.S. and European regulatory agencies are in agreement with the company’s Phase III trial design of Votrient +/- TRC105 in angiosarcoma patients.

The trial is powered at 80% to detect an improvement in median progression free survival from 4.0 months to 7.3 months. The analyst believes it's likely TRC105 will achieve both FDA and EMA approval if the combination repeats its initial Phase 1b/2 performance during which five angiosarcoma patients showed an mPFS of >12.9 months (two responses are still ongoing). TRACON anticipates initiating the trial by YE16 and the analyst believes the trial could be fully enrolled within two years.

No change to the price target of $14.

For an analyst ratings summary and ratings history on Tracon Pharmaceuticals click here. For more ratings news on Tracon Pharmaceuticals click here.

Shares of Tracon Pharmaceuticals closed at $6.73 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment